Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury.
- 1 August 1994
- journal article
- abstracts
- Published by Wolters Kluwer Health in Circulation
- Vol. 90 (2) , 944-951
- https://doi.org/10.1161/01.cir.90.2.944
Abstract
BACKGROUND: Smooth muscle cell proliferation and extracellular matrix accumulation are the principal mechanisms leading to vascular restenosis. We have previously demonstrated the growth-inhibitory effect of antisense oligomers targeting the c-myc proto-oncogene in human smooth muscle cells. The goal of this study was to investigate whether c-myc antisense oligomers reduce neointimal formation in balloon-denuded porcine coronary arteries. METHODS AND RESULTS: First, type I collagen synthesis, which reflects synthetic function, was markedly reduced following c-myc antisense oligomers in porcine vascular smooth muscle cells independent of the growth inhibition. These effects in vitro provided the rationale for assessing c-myc antisense oligomers in the prevention of neointima in vivo. Second, the efficiency of single transcatheter delivery of oligomers into denuded porcine coronary arteries was determined. Despite rapid plasma clearance following local delivery, oligomers persisted at the site of injection for at least 3 days, exceeding by severalfold their concentration in peripheral organs. Third, morphometric analyses were carried out in balloon-denuded coronary arteries at 1 month after transcatheter c-myc antisense oligomer administration. Maximal neointimal area was reduced from 0.80 +/- 0.17 mm2 in the control group (n = 12) to 0.24 +/- 0.06 mm2 in the antisense-treated group (n = 13, P < .01). Likewise, a significant reduction in maximal neointimal thickness was observed in the antisense-treated group (P < .01). These changes in vascular remodeling following denuding injury resulted in an increase in residual lumen from 64 +/- 6% in the control group to 81 +/- 5% in the antisense-treated group (P < .05). CONCLUSIONS: (1) Single transcatheter administration allowed for endoluminal delivery of oligomers to the site of coronary arterial injury. (2) C-myc antisense oligomers reduced the formation of neointima in denuded coronary arteries, implying a therapeutic potential of this approach for the prevention of coronary restenosis. (3) It is postulated that the c-myc proto-oncogene is involved in the process of vascular remodeling, regulating smooth muscle cell proliferation and extracellular matrix synthesis.Keywords
This publication has 26 references indexed in Scilit:
- Proliferative activity in peripheral and coronary atherosclerotic plaque among patients undergoing percutaneous revascularization.Journal of Clinical Investigation, 1993
- Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivoNature, 1992
- Organ distribution and stability of phosphorothioated oligodeoxyribonucleotides in miceBiopharmaceutics & Drug Disposition, 1992
- Selection of single-stranded DNA molecules that bind and inhibit human thrombinNature, 1992
- Direct intraarterial wall injection of microparticles via a catheter: A potential drug delivery strategy following angioplastyAmerican Heart Journal, 1991
- Regulation of differentiated properties and proliferation of arterial smooth muscle cells.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1990
- Cytodifferentiation and expression of alpha-smooth muscle actin mRNA and protein during primary culture of aortic smooth muscle cells. Correlation with cell density and proliferative state.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1989
- Destruction of a translationally controlled mRNA in Xenopus oocytes delays progesterone-induced maturation.Genes & Development, 1988
- Activation and repression of mammalian gene expression by the c-myc protein.Genes & Development, 1987
- Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplastyJournal of the American College of Cardiology, 1985